phenytoin	Paroxetine Hydrochloride	2	4	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	none	8183	none
phenytoin	Paroxetine Hydrochloride	2	4	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	none	8183	none
phenytoin	Paroxetine Hydrochloride	4	4	true	positive	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	none	8183	none
phenytoin	Paroxetine Hydrochloride	4	4	true	positive	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	none	8183	none
phenytoin	paroxetine	1	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	1	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	1	2	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	1	2	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	2	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	2	1	true	positive	When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone.  In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	2	2	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	2	2	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  		8183	32937	8183	D017374
phenytoin	paroxetine	2	4	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
phenytoin	paroxetine	2	4	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
phenytoin	paroxetine	4	2	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
phenytoin	paroxetine	4	2	true	positive	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
phenytoin	paroxetine	4	4	true	positive	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
phenytoin	paroxetine	4	4	true	positive	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		8183	32937	8183	D017374
Paroxetine Hydrochloride	paroxetine	4	2	false	none	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		none	32937	none	D017374
Paroxetine Hydrochloride	paroxetine	4	2	false	none	In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.  Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.  No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		none	32937	none	D017374
Paroxetine Hydrochloride	paroxetine	4	4	false	none	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		none	32937	none	D017374
Paroxetine Hydrochloride	paroxetine	4	4	false	none	No initial dosage adjustments are considered necessary when Paroxetine Hydrochloride Controlled-Release Tablets are coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).  		none	32937	none	D017374
